Inogen Q2 revenue up driven by higher demand for portable oxygen concentrators
INGN•Key figures
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Revenue | Slight Miss* | $95.10 million | $95.23 million (3 analysts) |
| Q2 Loss Per Share | $0.14 | ||
| Q2 Net Loss | $3.90 million | ||
| Q2 Adjusted EBITDA | Beat | $2.40 million | $1.71 million (3 analysts) |
| Q2 Gross Margin | 45.50% |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst coverage
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell".
- The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy".
- Wall Street's median 12-month price target for Inogen, Inc. is $12.00, about 82.9% above its August 5 closing price of $6.56.
